All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @elizajane1983 on TikTok · 65s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @elizajane1983's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I grew picked up, I want wood, I know I grew good enough
  2. 0:05I grew good enough, I grew good enough
  3. 0:10In a time she said, damn all of the night
  4. 0:19I grew picked up, I grew great
  5. 0:54Oh

@elizajane1983's 10-month Zepbound journey, fact-checked

Elizabeth

TikTok creator

28.3K viewsWatch on TikTok

Quick answer

This video documents a self-reported 10-month course of tirzepatide (Zepbound) in a creator who identifies as having hypothyroidism, with an affiliate relationship to IVIM Health. No specific medical claims are made verbally. The clinical relevance centers on the potential interaction between GLP-1-induced delayed gastric emptying and levothyroxine absorption, a consideration that endocrinologists have flagged but that rarely appears in patient-facing GLP-1 content.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @elizajane1983's 10-month Zepbound journey, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@elizajane1983's 10-month Zepbound journey, fact-checked" from Elizabeth. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video documents a self-reported 10-month course of tirzepatide (Zepbound) in a creator who identifies as having hypothyroidism, with an affiliate relationship to IVIM Health.

The reason this review is not generic is the source wording and the canonical claim label "glp1 10 months on zepbound glp1 journey zepbound journey glp1." In this clip, the useful excerpt is: "I grew picked up, I want wood, I know I grew good enough I grew good enough, I grew good enough In a time she said, damn all of the night I grew picked up, I grew great Oh" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide acts on both GIP and GLP-1 receptors, making it mechanistically distinct from semaglutide-only medications like Wegovy or Ozempic.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

This video documents a self-reported 10-month course of tirzepatide (Zepbound) in a creator who identifies as having hypothyroidism, with an affiliate relationship to IVIM Health.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • This video documents a self-reported 10-month course of tirzepatide (Zepbound) in a creator who identifies as having hypothyroidism, with an affiliate relationship to IVIM Health. No specific medical claims are made verbally. The clinical relevance centers on the potential interaction between GLP-1-induced delayed gastric emptying and levothyroxine absorption, a consideration that endocrinologists have flagged but that rarely appears in patient-facing GLP-1 content.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found average 22.5% body weight reduction with tirzepatide 15mg over 72 weeks, but individual results ranged widely.
  • Tirzepatide acts on both GIP and GLP-1 receptors, making it mechanistically distinct from semaglutide-only medications like Wegovy or Ozempic.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found average 22.5% body weight reduction with tirzepatide 15mg over 72 weeks, but individual results ranged widely.
  • Tirzepatide acts on both GIP and GLP-1 receptors, making it mechanistically distinct from semaglutide-only medications like Wegovy or Ozempic.
  • A 2023 case series in Thyroid journal identified that GLP-1-induced delayed gastric emptying can reduce levothyroxine absorption reliability in some patients.
  • FDA approval for Zepbound requires a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. It is not approved for general weight management in otherwise healthy adults.
  • FTC 2023 endorsement guidance states that affiliate disclosures must be clear and conspicuous, not buried in hashtag lists, a standard many GLP-1 creator posts technically fail.
  • This video contained no verbal medical claims. The transcript is song lyrics. Any implied health messaging comes from caption framing and hashtag context, not spoken content.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @elizajane1983 actually say?

Honestly? Almost nothing factual. The transcript from this 28K-view TikTok is song lyrics, not health commentary. The words captured are something like "I grew good enough" and "damn all of the night" repeated over a beat. This is a transformation video set to music, not a verbal claims video.

The actual information here comes from the caption, not the spoken content. The caption tells us the creator has been on Zepbound for 10 months, identifies as someone with hypothyroidism, and tags the IVIM Health affiliate program. That context matters more than anything said aloud in the clip.

So let's be clear about scope: we're fact-checking what a 10-month Zepbound journey video implies and what the caption signals, because the transcript itself gives us nothing to work with medically.

Does the science back this up?

The implied premise, that tirzepatide (Zepbound) produces meaningful weight loss over 10 months, is well-supported by evidence. But the hypothyroidism angle in the hashtags deserves scrutiny, because it's more complicated than most GLP-1 content acknowledges.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that tirzepatide at the highest dose produced an average 22.5% body weight reduction over 72 weeks in adults with obesity. Ten months sits inside that window. Those are real, significant numbers.

The hypothyroidism piece is trickier. Levothyroxine absorption can be affected by changes in gut motility, which GLP-1 receptor agonists slow significantly. A 2023 case series in Thyroid journal flagged that some patients on GLP-1 agonists required levothyroxine dose adjustments. Whether the creator experienced this isn't clear, but it's clinically relevant context that most TikTok transformation videos completely skip.

What did they get wrong (or right)?

There's nothing medically wrong said out loud here, because nothing medically specific was said. That's actually a point in this video's favor compared to many GLP-1 creator posts that make explicit dosing claims or promise specific outcomes.

What the video does implicitly suggest, through hashtags and before-and-after framing, is that a 10-month Zepbound run produces dramatic visible results. That implication is broadly consistent with clinical data, though individual results vary significantly. SURMOUNT-1 showed a wide distribution of outcomes, not a uniform 22% loss for every participant.

The IVIM Health affiliate tag is worth flagging. This is a commercial relationship, and viewers deserve to know that. The FTC requires disclosure of material connections in sponsored content. Hashtag disclosure like "#ivimaffiliate" is technically present but easy to miss in a list of 11 other hashtags. That's a gray area that the FTC has pushed back on in enforcement letters.

  • No false medical claims made verbally: accurate
  • Hypothyroidism complexity not addressed: a gap, not a lie
  • Affiliate disclosure present but minimized: borderline compliant

What should you actually know?

If you have hypothyroidism and you're considering a GLP-1 medication like tirzepatide, talk to the clinician managing your thyroid before you start. This is not a scare tactic. Slowed gastric emptying from GLP-1 agonists can change how consistently your levothyroxine absorbs, and an undertreated thyroid can actually make weight loss harder. Your thyroid panel may need monitoring after you start.

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It is not a lifestyle supplement. It works through dual GIP and GLP-1 receptor agonism, which is a different mechanism than semaglutide-only drugs like Wegovy.

Transformation videos are not clinical data. A single person's 10-month result, however dramatic, tells you nothing reliable about what your body will do. The variance in GLP-1 outcomes is significant, and factors like baseline weight, diet, activity, other medications, and genetics all play a role that no before-and-after photo can capture.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Elizabeth · TikTok creator

28.3K views on this video

10 months on Zepbound! GLP1 journey Zepbound journey. #glp1 #weightloss #glp1community #glp1journey#healthjourney #zepboundjourney #hypothyroidism #weightlosstransformation #fitnessmotivation #zepbou

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) found average 22.5% body?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found average 22.5% body weight reduction with tirzepatide 15mg over 72 weeks, but individual results ranged widely.

What does the video say about tirzepatide acts on both gip?

Tirzepatide acts on both GIP and GLP-1 receptors, making it mechanistically distinct from semaglutide-only medications like Wegovy or Ozempic.

What does the video say about a 2023 case series in thyroid journal identified?

A 2023 case series in Thyroid journal identified that GLP-1-induced delayed gastric emptying can reduce levothyroxine absorption reliability in some patients.

What does the video say about fda approval for zepbound requires a bmi of 30?

FDA approval for Zepbound requires a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. It is not approved for general weight management in otherwise healthy adults.

What does the video say about ftc 2023 endorsement guidance states?

FTC 2023 endorsement guidance states that affiliate disclosures must be clear and conspicuous, not buried in hashtag lists, a standard many GLP-1 creator posts technically fail.

What does the video say about this video contained no verbal medical claims. the transcript?

This video contained no verbal medical claims. The transcript is song lyrics. Any implied health messaging comes from caption framing and hashtag context, not spoken content.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Elizabeth, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.